Effectiveness and safety of interferon α2a as an add-on treatment for refractory Behçet’s uveitis
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 10
Abstract
The objective of this study was to investigate the effectiveness and safety of interferon (IFN) α2a as an add-on treatment for refractory Behçet’s uveitis (BU). In this retrospective cohort study, 30 refractory BU patients who received IFNα2a treatment in Peking Union Medical College Hospital between February 2015 and June 2018 were consecutively included. IFNα2a was used mainly as an add-on treatment for BU patients who underwent relapse under corticosteroids and conventional immunosuppressive agents. The primary outcome was treatment success rate before and after initiation of IFNα2a. Changes in ocular relapse rates, disease activity, corticosteroid- and immunosuppressant-sparing effects, as well as side effects were secondary outcomes. A total of 30 patients (27 males and 3 females) with a mean age of 30.5 ± 8.7 years were included. Twenty-one patients (70%) were treated with at least 2 immunosuppressive agents before the initiation of IFNα2a. Treatment success was achieved in 26 patients (86.7%), and the median uveitis relapse rate decreased from 7.3 (range 2–12) to 0 (range 0–6) per patient-year (p = 0.000002) during a mean follow-up of 21.7 ± 7.5 months, corticosteroids were lowered in 25 cases (83.3%) and completely withdrawn in four (13.3%). In addition, immunosuppressive agents were reduced in number and dosage in 22 (73.3%) and 29 patients (96.7%), respectively, and were completely withdrawn in 12 cases (40%). No severe adverse events were observed and serum autoantibodies remained negative during the treatment of IFNα2a. IFNα2a is effective and relatively safe in refractory BU, with significant steroid- and immunosuppressant-sparing effects.Keywords
Funding Information
- CAMS Initiative for Innovative Medicine (2016-I2M-1-013)
- Chinese Academy of Medical Sciences (1007-1002-1-19)
- National Key Research and Development Program: “Precise Medical Research” (2016YFC0906201)
- National Natural Science Foundation of China (81571598)
This publication has 36 references indexed in Scilit:
- The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteriaJournal of the European Academy of Dermatology and Venereology, 2013
- Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet's Uveitis Refractory to Conventional TreatmentsOphthalmology, 2010
- Behcet’s disease in Iran: analysis of 6500 casesInternational Journal of Rheumatic Diseases, 2010
- Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealedJournal of Clinical Investigation, 2009
- Interferon Alpha Treatment and Thyroid DysfunctionEndocrinology and Metabolism Clinics of North America, 2007
- Vogt-Koyanagi-Harada DiseaseInternational Ophthalmology Clinics, 2006
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot studyBritish Journal of Ophthalmology, 1998
- Beneficial effects of interferon‐α2b in Behçet's diseaseArthritis & Rheumatism, 1993
- Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disordersClinical Immunology and Immunopathology, 1992